• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

  • 4.3 市場の抑制要因

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 サプライヤーの交渉力

    • 4.4.2 消費者の交渉力

    • 4.4.3 新規参入の脅威

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション

  • 5.1 薬物

    • 5.1.1 ビグアナイド

      • 5.1.1.1 メトホルミン

    • 5.1.2 α-グルコシダーゼ阻害剤

      • 5.1.2.1 α-グルコシダーゼ阻害剤

    • 5.1.3 ドーパミン-D2受容体作動薬

      • 5.1.3.1 ブロモクリプチン（サイクロセット）

    • 5.1.4 ナトリウム-グルコース共輸送担体-2（SGLT-2）阻害薬

      • 5.1.4.1 インボカーナ（カナグリフロジン）
      • 5.1.4.2 ジャーディアンス（エンパグリフロジン）
      • 5.1.4.3 ファルキシガ／フォルキシガ（ダパグリフロジン）
      • 5.1.4.4 スグラット（イプラグリフロジン）

    • 5.1.5 ジペプチジルペプチダーゼ-4（DPP-4）阻害剤

      • 5.1.5.1 ジャヌビア（シタグリプチン）
      • 5.1.5.2 オングリザ（サキサグリプチン）
      • 5.1.5.3 トラジェンタ（リナグリプチン）
      • 5.1.5.4 ビピディア／ネシーナ（アログリプチン）
      • 5.1.5.5 ガルバス（ビルダグリプチン）

    • 5.1.6 スルホニル尿素

      • 5.1.6.1 スルホニル尿素

    • 5.1.7 メグリチニド

      • 5.1.7.1 メグリチニド

  • 5.2 地域別

    • 5.2.1 北米

      • 5.2.1.1 米国
      • 5.2.1.2 カナダ
      • 5.2.1.3 その他の北米

    • 5.2.2 ヨーロッパ

      • 5.2.2.1 フランス
      • 5.2.2.2 ドイツ
      • 5.2.2.3 イタリア
      • 5.2.2.4 スペイン
      • 5.2.2.5 英国
      • 5.2.2.6 ロシア
      • 5.2.2.7 その他のヨーロッパ

    • 5.2.3 ラテンアメリカ

      • 5.2.3.1 メキシコ
      • 5.2.3.2 ブラジル
      • 5.2.3.3 その他のラテンアメリカ

    • 5.2.4 アジア太平洋

      • 5.2.4.1 日本
      • 5.2.4.2 韓国
      • 5.2.4.3 中国
      • 5.2.4.4 インド
      • 5.2.4.5 オーストラリア
      • 5.2.4.6 ベトナム
      • 5.2.4.7 マレーシア
      • 5.2.4.8 インドネシア
      • 5.2.4.9 フィリピン
      • 5.2.4.10 タイ
      • 5.2.4.11 その他のアジア太平洋

    • 5.2.5 中東・アフリカ

      • 5.2.5.1 サウジアラビア
      • 5.2.5.2 イラン
      • 5.2.5.3 エジプト
      • 5.2.5.4 オマーン
      • 5.2.5.5 南アフリカ
      • 5.2.5.6 その他の中東・アフリカ

• 6 市場指標

  • 6.1 1型糖尿病人口

  • 6.2 2型糖尿病人口

• 7 競合情勢

  • 7.1 企業プロファイル

    • 7.1.1 Sanofi S.A

    • 7.1.2 Eli Lilly and Company

    • 7.1.3 AstraZeneca

    • 7.1.4 Astellas Pharma Inc

    • 7.1.5 Johnson & Johnson (Janssen Pharmaceuticals)

    • 7.1.6 Boehringer Ingelheim

    • 7.1.7 Merck And Co

    • 7.1.8 Takeda

    • 7.1.9 Bristol Myers Squibb

    • 7.1.10 Novartis

    • 7.1.11 Pfizer

  • 7.2 Company Share Analysis

    • 7.2.1 Sanofi S.A

    • 7.2.2 Eli Lilly and Company

    • 7.2.3 AstraZeneca

    • 7.2.4 Merck and Co

    • 7.2.5 その他

• 8 市場機会と今後の動向

The Oral Anti-Diabetic Drugs Market size is estimated at USD 46.82 billion in 2024, and is expected to reach USD 57.44 billion by 2029, growing at a CAGR of 4.17% during the forecast period (2024-2029).

The market is estimated to reach a value of more than USD 52 billion by 2027.

The COVID-19 pandemic has had a substantial impact on the oral anti-diabetic drugs market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of the oral anti-diabetic drugs market. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the oral anti-diabetic drugs market's growth globally.

According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed cases of Type 1 and Type 2 diabetes is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure worldwide are indications of the increasing usage of anti-diabetic drugs. Technological advancements and innovations have increased over the period leading to several modifications either in the drugs or the formulations being developed.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Oral Anti Diabetic Drugs Market Trends

Biguanide Segment Occupies the Highest Market Share in the Oral Anti-Diabetic Drugs Market in the current year

Biguanide Segment holds the highest share of about 45% in the Oral Anti-Diabetic Drugs Market in the current year.

Metformin is classified as a biguanide used for treating type 2 diabetes. It is prescribed for its off-label use in people with conditions such as insulin resistance. Since the introduction of metformin in T2DM therapy, many patients were treated successfully with this globally available medication. It includes a favorable risk/benefit profile recommended by IDF guidelines as a first-line drug. Long-term positive experience with the use of metformin, strong evidence of clinical efficacy, safety, high adherence rate, low cost, general availability, and cost-effectiveness are the contributing factors to the high market share. The World Health Organization put metformin on the list of essential medicines: 'medicines that satisfy the priority of health care needs of the population.'

Biguanides are a class of medications used to treat type 2 diabetes. They work by reducing the production of glucose that occurs during digestion. Metformin is the only biguanide currently available in most countries for treating diabetes. Glucophage (metformin) and Glucophage XR (metformin extended release) are well-known brand names for these drugs. Others include Fortamet, Glumetza, and Riomet. Metformin is also available in combination with several other types of diabetes medications, such as sulfonylureas.

In July 2022, Zydus Lifesciences announced that it had received final approval to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.

Owing to the factors above and the increasing prevalence, the market will likely continue to grow.

Asia-Pacific Region is Expected to witness highest CAGR in the Oral Anti-Diabetic Drugs Market over the forecast period

The Asia-Pacific region is expected to register a CAGR of more than 4% over the forecast period.

According to International Diabetes Federation, 90 million adults lived with diabetes in the IDF South-East Asia Region and 206 million adults in the IDF Western Pacific Region in 2021. This figure is estimated to increase to 113 million and 238 million by 2030. The use of oral anti-diabetes drugs is rising because new-generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.

China and Japan are recognized as potential developing markets in the Asia-Pacific region due to the growing diabetic population. Japan is a mature market with associated challenges, like slow economic growth, an aging population, and increased competition. The country is witnessing a significant increase in generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.

Diabetes reduces lifespan, and people with the disease are likely to experience blindness and be hospitalized for amputations, kidney failure, heart attacks, strokes, and heart failure. First-line therapy used in patients with T2D is metformin monotherapy. Other options must be considered when metformin is contraindicated or not tolerated or when treatment goals are not achieved after three months of use at the maximum tolerated dose. The growing spectrum of diabetes mellitus drugs includes dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 agonists, generally used to supplement treatment with metformin.

The market is expected to grow during the forecast period due to the factors above.

Oral Anti Diabetic Drugs Industry Overview

The oral anti-diabetes drug market is moderately fragmented, with major manufacturers like Eli Lilly, AstraZeneca, Sanofi, Janssen Pharmaceuticals, etc., having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

  • 4.3 Market Restraints

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Bargaining Power of Suppliers

    • 4.4.2 Bargaining Power of Consumers

    • 4.4.3 Threat of New Entrants

    • 4.4.4 Threat of Substitute Products and Services

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION

  • 5.1 Drugs

    • 5.1.1 Biguanides

      • 5.1.1.1 Metformin

    • 5.1.2 Alpha-glucosidase inhibitors

      • 5.1.2.1 Alpha-glucosidase Inhibitors

    • 5.1.3 Dopamine -D2 Receptor Agonist

      • 5.1.3.1 Bromocriptin (Cycloset)

    • 5.1.4 Sodium-glucose Cotransport -2 (SGLT-2) inhibitor

      • 5.1.4.1 Invokana (Canagliflozin)
      • 5.1.4.2 Jardiance (Empagliflozin)
      • 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
      • 5.1.4.4 Suglat (Ipragliflozin)

    • 5.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

      • 5.1.5.1 Januvia (Sitagliptin)
      • 5.1.5.2 Onglyza (Saxagliptin)
      • 5.1.5.3 Tradjenta (Linagliptin)
      • 5.1.5.4 Vipidia/Nesina (Alogliptin)
      • 5.1.5.5 Galvus (Vildagliptin)

    • 5.1.6 Sulfonylureas

      • 5.1.6.1 Sulfonylureas

    • 5.1.7 Meglitinides

      • 5.1.7.1 Meglitinides

  • 5.2 Geography

    • 5.2.1 North America

      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Rest of North America

    • 5.2.2 Europe

      • 5.2.2.1 France
      • 5.2.2.2 Germany
      • 5.2.2.3 Italy
      • 5.2.2.4 Spain
      • 5.2.2.5 United Kingdom
      • 5.2.2.6 Russia
      • 5.2.2.7 Rest of Europe

    • 5.2.3 Latin America

      • 5.2.3.1 Mexico
      • 5.2.3.2 Brazil
      • 5.2.3.3 Rest of Latin America

    • 5.2.4 Asia-Pacific

      • 5.2.4.1 Japan
      • 5.2.4.2 South Korea
      • 5.2.4.3 China
      • 5.2.4.4 India
      • 5.2.4.5 Australia
      • 5.2.4.6 Vietnam
      • 5.2.4.7 Malaysia
      • 5.2.4.8 Indonesia
      • 5.2.4.9 Philippines
      • 5.2.4.10 Thailand
      • 5.2.4.11 Rest of Asia-Pacific

    • 5.2.5 Middle East and Africa

      • 5.2.5.1 Saudi Arabia
      • 5.2.5.2 Iran
      • 5.2.5.3 Egypt
      • 5.2.5.4 Oman
      • 5.2.5.5 South Africa
      • 5.2.5.6 Rest of Middle East and Africa

• 6 MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population

  • 6.2 Type 2 Diabetes Population

• 7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles

    • 7.1.1 Sanofi S.A

    • 7.1.2 Eli Lilly and Company

    • 7.1.3 AstraZeneca

    • 7.1.4 Astellas Pharma Inc

    • 7.1.5 Johnson & Johnson (Janssen Pharmaceuticals)

    • 7.1.6 Boehringer Ingelheim

    • 7.1.7 Merck And Co

    • 7.1.8 Takeda

    • 7.1.9 Bristol Myers Squibb

    • 7.1.10 Novartis

    • 7.1.11 Pfizer

  • 7.2 Company Share Analysis

    • 7.2.1 Sanofi S.A

    • 7.2.2 Eli Lilly and Company

    • 7.2.3 AstraZeneca

    • 7.2.4 Merck and Co

    • 7.2.5 Others

• 8 MARKET OPPORTUNITIES AND FUTURE TRENDS